Advanced Search

Home > Journals > Minerva Ginecologica > Past Issues > Minerva Ginecologica 2004 February;56(1) > Minerva Ginecologica 2004 February;56(1):91-104



A Journal on Obstetrics and Gynecology

Indexed/Abstracted in: EMBASE, PubMed/MEDLINE, Scopus, Emerging Sources Citation Index

Frequency: Bi-Monthly

ISSN 0026-4784

Online ISSN 1827-1650


Minerva Ginecologica 2004 February;56(1):91-104


Biologic therapy and epithelial ovarian cancer

Porpiglia M., Vicelli R., Durando A., Fracchioli S., Puopolo M., Katsaros D., Bellino R., Benedetto C.

The identification of new molecular prognostic and predictive factors for ovarian cancer may contribute in deciding individual therapeutic strategies; on the other hand, there has been growing interest in new biologic therapies to correct molecular or genic lesions of neoplastic cells (genic therapy), or to activate the specific immune response (immunological therapy). Chemotherapy collateral toxic effects, as myelotoxicity, should be reduced through transfection of genes that modulate drug resistance in stem cells. The data at present available suggest then the potential role of these new treatments, are more specific and less toxic than current therapies; hovewer, other biological-molecular studies are required to obtain the clinical applications of the results. Aim of this study is to provide a review of the most interesting data in ovarian cancer biologic therapy.

language: Italian


top of page